Determination of the analgesic components of Spasmomigraine tablet by liquid chromatography with ultraviolet detection.

A procedure was developed for the determination of the analgesic components of Spasmomigraine tablets, which are ergotamine (I), propyphenazone (II), caffeine (III), camylofin (IV), and mecloxamine (V). They were subjected to high-performance liquid chromatography on a column (300 x 3.9 mm, 10 rlm particle size) packed with micro-Bondapak C18. Separations were achieved with the mobile phase methanol-water-triethylamine (60 + 40 + 0.1, v/v/v) flowing at a rate of 1.5 mL/min, and quantitative determination was performed at 254 nm at ambient temperature for I-III; acetonitrile-25 mM KH2PO4-acetic acid (45 + 55 + 0.2, v/v/v), flowing at a rate of 1.5 mL/min and detection at 234 nm at ambient temperature, was used for IV and V. Methyl paraben was used as an internal standard. The detection limits were 0.35 (I), 5.0 (11), 1.5 (111), 3.0 (IV), and 2.0 microg/mL (V). The method was accurate (mean recovery 98+/-2%, n = 4) and precise (coefficient of variation <5%, n = 5). The proposed method is rapid and sensitive and, therefore, suitable for the routine control of these ingredients in multicomponent dosage forms.

Spectrofluorimetric determination of warfarin sodium by using N1-methylnicotinamide chloride as a fluorigenic agent.

A spectrofluorimetric method is described for the determination of drugs containing active methylene groups adjacent to carbonyl groups. The method was applied successfully to the determination of warfarin sodium in laboratory-prepared mixtures, in commercial tablets, and in spiked human plasma samples. Finally, the method was applied to the determination of the steady-state concentration of warfarin sodium in the blood of a hospitalized patient. The method involves the reaction of warfarin sodium with 0.2 ml (0.4 x 10(-3)M) N1-methylnicotinamide chloride reagent in the presence of 3 mL 1.0N NaOH and cooling in ice for 8 min, followed by adjustment of the pH to 2.0, using formic acid and heating for 4 min, whereby a highly fluorescent reaction product is produced. The optimal wavelengths of excitation and emission were determined by using a synchronous wavelength search and found to be 284 and 354 nm, respectively. The standard curves were linear over a concentration range of 50-1500 ng/mL in both aqueous solutions and spiked human plasma samples. The mean recoveries (+/- standard deviation) were 101.157 (+/-1.33) and 95.73 (+/-1.88%) for aqueous solutions and spiked human plasma samples, respectively. The method showed good specificity and precision. The proposed method is simple and economical because of its minimal instrumentation and chemicals requirements. Nevertheless, it is highly sensitive, specific, and reproducible. Accordingly, it is suitable for quality-control applications, drug monitoring, and bioavailability and bioequivalency studies.

Liquid chromatographic determination of fluoxetine.

A simple, accurate and sensitive high pressure liquid chromatographic technique is described for the determination of fluoxetine in the capsule dosage form, human plasma and in biological fluid. Analysis is performed with a reversed phase-C18 column with ultraviolet detection at 228 nm. The isocratic mobile phase (1.5 ml/min.) consists of acetonitrile and triethylamine buffer (48 + 52, V/V). A linear calibration model (correlation coefficient 0.99863) was developed using pyridoxine as internal standard. The retention times were 2.10 and 3.20 min for pyridoxine and fluoxetine, respectively. The method was applied for the quantitation of fluoxetine in spiked human plasma samples. The detection limit is 5 microg/l and the absorbance varies with fluoxetine concentrations in the range (10-300) microg/l. The mean % recovery +/- S.D. was found to be 97.99% +/- 2.39. The proposed method was applied successfully for monitoring of fluoxetine in human plasma after single dose administration of one prozac capsule.